TABLE 1.
Characteristics at index date before and after stabilised inverse probability of treatment weighting and follow‐up status
| Before weighting |
After weighting |
||||||
|---|---|---|---|---|---|---|---|
| Variable name | Response | Untreated (N = 672) |
Treated (N = 723) |
Abs Stddiff |
Untreated (N = 639) |
Treated (N = 720) |
Abs Stddiff |
| Study site | GHS | 110 (16%) | 157 (22%) | 0.159 | (21%) | (20%) | 0.057 |
| HFHS | 315 (47%) | 292 (40%) | (44%) | (42%) | |||
| KPHI | 45 (7%) | 52 (7%) | (7%) | (8%) | |||
| KPNW | 202 (30%) | 222 (31%) | (28%) | (30%) | |||
| Sex | Female | 230 (34%) | 234 (32%) | 0.014 | (33%) | (34%) | 0.046 |
| Male | 442 (66%) | 489 (68%) | (67%) | (66%) | |||
| Race | ASINPI | 42 (6%) | 57 (8%) | 0.293 | (7%) | (7%) | 0.057 |
| Black/African American |
298 (44%) | 243 (34%) | (39%) | (37%) | |||
| White | 291 (43%) | 401 (55%) | (50%) | (50%) | |||
| Unknown | 41 (6%) | 22 (3%) | (5%) | (6%) | |||
| Cirrhosis | Yes | 157 (23%) | 333 (46%) | (33%) | (34%) | 0.020 | |
| FIB4 | ≤1.21 | 137 (20%) | 88 (12%) | 0.290 | (17%) | (16%) | 0.026 |
| 1.21–5.88 | 412 (61%) | 488 (67%) | (63%) | (64%) | |||
| >5.88 | 81 (12%) | 123 (17%) | (15%) | (14%) | |||
| Missing | 42 (6%) | 24 (3%) | (5%) | (5%) | |||
| FIB4 | <3.25 | 433 (64%) | 422 (58%) | 0.220 | (63%) | (61%) | 0.040 |
| ≥3.25 | 197 (29%) | 277 (38%) | (32%) | (34%) | |||
| Missing | 42 (6%) | 24 (3%) | (5%) | (5%) | |||
| BMI | <25 | 144 (21%) | 109 (15%) | 0.304 | (19%) | (19%) | 0.009 |
| 25 < 30 | 181 (27%) | 205 (28%) | (28%) | (28%) | |||
| ≥30 | 271 (40%) | 370 (51%) | (44%) | (44%) | |||
| Missing | 76 (11%) | 39 (5%) | (8%) | (8%) | |||
| HCV Genotype | 1 | 350 (52%) | 535 (74%) | 0.609 | (64%) | (64%) | 0.013 |
| 2 | 51 (8%) | 84 (12%) | (9%) | (10%) | |||
| 3/Unknown | 271 (40%) | 104 (14%) | (27%) | (27%) | |||
| Weighted Charlson-Deyo | 0 | 71 (11%) | 32 (4%) | 0.238 | (8%) | (8%) | 0.012 |
| Comorbidity score | 1 | 163 (24%) | 176 (24%) | (24%) | (24%) | ||
| ≥2 | 438 (65%) | 515 (71%) | (68%) | (69%) | |||
| Hypertension | Yes | 273 (41%) | 146 (20%) | <.001 | (31%) | (31%) | 0.011 |
| Hyperlipidaemia | Yes | 128 (19%) | 258 (36%) | <.001 | (26%) | (28%) | 0.033 |
| Statins (ever used) | Yes | 357 (53%) | 385 (53%) | 0.963 | (54%) | (53%) | 0.014 |
| Age (mean ± SD) | 59.7 ± 9.9 | 59.1 ± 7.9 | 0.066 | 59.2 ± 10.6 | 58.8 ± 9.6 | 0.043 | |
| HbAlc (mean ± SD) | 7.3 ± 1.9 | 7.2 ± 1.5 | 0.025 | 7.3 ± 2.1 | 7.2 ± 1.7 | 0.027 | |
| ACS | |||||||
| F/U in years (median, IQR) | 3.1 (1.6–6.7) | 2.6 (1.8–4.4) | |||||
| Event (n) | 105 | 38 | |||||
| End-stage renal disease | |||||||
| F/U in years (median, IQR) | 3.3 (1.7–7.0) | 2.6 (1.8–4.2) | |||||
| Event (n) | 117 | 42 | |||||
| Ischaemic stroke | |||||||
| F/U in years (median, IQR) | 3.3 (1.8–6.8) | 2.6 (1.8–4.4) | |||||
| Event (n) | 72 | 25 | |||||
| Retinopathya | |||||||
| F/U in years (median, IQR) | 2.5 (1.2–5.4) | 2.6 (1.8–3.9) | |||||
| Event (n) | 141 | 46 | |||||
Abs Stddiff, absolute value of standardised difference; FIB4, fibrosis-4 index; HbAlc, haemoglobin A1c; ASINPI, Asian American, American Indian, and Pacific Islander; GHS, Geisinger Clinic; HFHS, Henry Ford Health System; KPHI, Kaiser Permanente Hawai'I; KPNW, Kaiser Permanente Northwest; F/U, follow-up.
a
Retinopathy cases within 1 year post index were excluded.